Page last updated: 2024-10-27

gliclazide and Cognition Disorders

gliclazide has been researched along with Cognition Disorders in 1 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Galan, BE1
Zoungas, S1
Chalmers, J1
Anderson, C1
Dufouil, C1
Pillai, A1
Cooper, M1
Grobbee, DE1
Hackett, M1
Hamet, P1
Heller, SR1
Lisheng, L1
MacMahon, S1
Mancia, G1
Neal, B1
Pan, CY1
Patel, A1
Poulter, N1
Travert, F1
Woodward, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for gliclazide and Cognition Disorders

ArticleYear
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    Diabetologia, 2009, Volume: 52, Issue:11

    Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A

2009